CVS Health said on 4 November that it “intends to separate into two independent, publicly traded companies”, in a release filed with the SEC the same morning as its third-quarter results. In those results it raised its 2026 cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion: a $4.0 billion, or about 35%, increase, by our arithmetic.
Third-quarter revenue rose 5.4% to $108.4 billion and adjusted EPS was $2.09, against $1.60 a year earlier. The adjusted EPS guide moved to at least $8.20, from a range of $7.90 to $8.10.
Business Pill · Vertical Integration
An evergreen Business Engineer explainer on vertical integration. It teaches the general idea only and does not discuss CVS Health.
The key insight: CVS Health plans to separate into an insurer-and-PBM company and a pharmacy company by the first half of 2028, and its results the same morning raised the 2026 operating cash flow floor to at least $15.5 billion from at least $11.5 billion, a $4.0 billion or about 35% increase by our arithmetic; about half of the nine-month cash flow rise came from a working-capital swing.
The planned split creates a healthcare solutions company, “comprising Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health”, which keeps the CVS Health name in the interim, and a pharmacy company named CVS Pharmacy, comprising about 9,000 pharmacies, mail pharmacy, MinuteClinic and “the Health100 technology services business”.
Health100 is where CVS puts its AI language. The separation release says Health100 “will deliver AI-native products and services designed to address today’s affordability, access and experience challenges in healthcare”, and that “Both companies remain committed to realizing the tremendous potential of Health100”. By the company’s own description, then, that technology unit sits with the pharmacy company, while the insurer and the pharmacy benefit manager go to the other side.
CVS says the separation is expected to be completed in the first half of 2028 and is intended to be tax-free to CVS Health and its shareholders. The release says David Joyner, currently chairman and CEO, is to lead the healthcare solutions company, and Prem Shah, currently group president, is to be CEO of CVS Pharmacy.
CVS Health’s 2026 cash flow from operations guidance: at least $15.5 billion, raised from at least $11.5 billion, per its third-quarter 2026 release filed on 4 November 2026 (8-K Exhibit 99.1). The $4.0 billion and ~35% change are our arithmetic.
Raises FY26 Guide: 🔹 Adj. EPS: At least $8.20 (Est. $8.04) 🟢; from $7.90-$8.10 🔹 Revenue: At least $420.0B (Est. $417.73B) 🟢 🔹 GAAP EPS: At least $6.98 🔹 Cash Flow From Operations: At least $15.5B; from at least $11.5B
Segments: 🔹 Health Care Benefits: $36.86B; Adj. Op. Income $0.91B; +2.4% YoY 🔹 Health Services: $53.96B; Adj. Op. Income $2.11B; +9.5% YoY 🔹 Pharmacy & Consumer Wellness: $35.50B; Adj. Op. Income $1.64B; -2.0% YoY 🔹 Medical Benefit Ratio: 91.3%; -150 bps YoY
Other Q3 Metrics: 🔹 Cash Flow From Operations: $15.3B YTD 🔹 Medical Membership: 26.1 million
Comments: 🔸 “We continue to advance our strategy by improving the consumer experience, lowering health care costs, and connecting care for the people we serve.” — David Joyner, CVS Health Chairman and CEO
Wall St Engine’s earnings card for CVS Health’s third quarter of 2026, posted on 4 November. It lists revenue of $108.40 billion against a $104.69 billion estimate, adjusted EPS of $2.09 against $1.65, and the raised full-year guidance, including cash flow from operations of at least $15.5 billion, up from at least $11.5 billion. The piece checks each figure against CVS’s filed release.
The Cash Flow Number
The release shows cash flow from operations of $15,318 million for the nine months to 30 September, against $7,249 million a year earlier, about 2.1 times. The new full-year floor of $15.5 billion is only about $0.2 billion above what CVS had already generated by the end of September, by our arithmetic.
Part of the jump is working capital. The cash flow statement shows the change in operating assets and liabilities added $3,556 million in the first nine months, against a $453 million drag a year earlier. That swing of about $4.0 billion is about half of the $8.1 billion year-over-year rise in operating cash flow, by our arithmetic.
Where the Quarter Came From
The release attributes the adjusted EPS increase “primarily due to improved adjusted operating income in the Health Care Benefits segment”. Health Care Benefits adjusted operating income rose to $912 million from $314 million, and its medical benefit ratio fell to 91.3% from 92.8%, which the release attributes to “improved underlying performance in the Government business”. Medical membership was 26.1 million.
Health Services revenue rose 9.5% to $53,964 million, with adjusted operating income up 2.7%. Pharmacy & Consumer Wellness revenue fell 2.0% to $35,498 million, which the release attributes partly to “regulatory-related price reductions on certain drugs”, while its adjusted operating income rose 10.6%.
CVS says the guidance raise reflects the Health Care Benefits and Pharmacy & Consumer Wellness segments, “while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds”. Wall St Engine’s earnings card put consensus at $104.69 billion of revenue and $1.65 of adjusted EPS.
What the Risk Factors Say
The 10-Q adds one risk factor heading that was not in the 2025 10-K: “CVS Health is subject to risks related to its intention to separate into two independent, publicly traded companies.” It runs to 438 words, by our count, and is the only heading in the quarter’s Item 1A; the second-quarter 10-Q reported no material changes.
The new text warns that the separation “will require significant time and attention from CVS Health’s senior management and employees”, and that “There can be no assurances that CVS Health will be able to complete the proposed separation on the terms or on the timeline that was announced, if at all”.
As we read the releases, the cash and the split arrive together: CVS had generated $15.3 billion of operating cash in nine months, and about $4.0 billion of the year-over-year rise came from the change in operating assets and liabilities, by our arithmetic.
As we read the separation release, the company’s AI language attaches to Health100, which goes with CVS Pharmacy, not with Aetna or CVS Caremark.
CVS Health separation release, 4 November 2026
“Both companies remain committed to realizing the tremendous potential of Health100, which will deliver AI-native products and services designed to address today’s affordability, access and experience challenges in healthcare.”
Three Implications
FOR SHAREHOLDERS The separation is intended to be tax-free to CVS Health and its shareholders, who would own shares in both companies; completion is expected in the first half of 2028.
FOR THE CASH GUIDE The new floor of at least $15.5 billion is about $0.2 billion above the $15.3 billion generated in nine months, by our arithmetic.
FOR THE AI UNIT Health100 is part of the retail pharmacy and community healthcare company, according to the 10-Q, alongside retail pharmacy, mail pharmacy and MinuteClinic.
The framework says: “Industries get rebuilt around AI-native architectures rather than retrofitted onto pre-AI ones.”
As we read it, CVS’s release uses the same word for Health100, which it says will deliver “AI-native products and services”; the split decides which of the two companies carries that unit. The framework does not discuss CVS.
The separation release we read gives no revenue or profit figure for either company, although its cautionary statement refers to “the forecast full year 2026 revenue and adjusted operating income of each company”; completion depends on, among other conditions, the effectiveness of a Form 10 registration statement. The releases do not say how Health100 makes money or what it earns. We did not read the 8 a.m. ET call. The fourth-quarter cash flow figure is our arithmetic on a floor, not a company forecast.
This Week In The AI Supercycle
Anthropic’s Reality Check, The Capital Squeeze, & The New World Order
This week’s issue: for two years the AI build-out was priced as a growthstory. This week it started being priced as a credit story.
CVS plans to separate into an insurer-and-PBM company and a pharmacy company by the first half of 2028, with its Health100 AI-native unit going to CVS Pharmacy. In the same morning’s results it raised its 2026 operating cash flow floor by $4.0 billion to $15.5 billion, about 35%, by our arithmetic, after generating $15.3 billion in nine months.
A note on sourcing. Figures and quotations are from CVS Health’s third-quarter 2026 results release and separation release, both filed with the SEC on 4 November 2026, and its Q3 2026 Form 10-Q. Consensus figures are as cited by Wall St Engine. Changes, multiples and the risk-factor word count are our arithmetic.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
